Skip to main navigation Skip to search Skip to main content

NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma

  • Eudocia Q. Lee
  • , Peixin Zhang
  • , Patrick Y. Wen
  • , Elizabeth R. Gerstner
  • , David A. Reardon
  • , Kenneth D. Aldape
  • , John F. deGroot
  • , Edward Pan
  • , Jeffrey J. Raizer
  • , Lyndon J. Kim
  • , Steven J. Chmura
  • , H. Ian Robins
  • , Jennifer M. Connelly
  • , James D. Battiste
  • , John L. Villano
  • , Naveed Wagle
  • , Ryan T. Merrell
  • , Merideth M. Wendland
  • , Minesh P. Mehta

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Fingerprint

Dive into the research topics of 'NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience

Agricultural and Biological Sciences